Merck Reports Q2 2025 Financial Results and Stock Outlook
Merck reported a 2% decrease in worldwide sales for Q2 2025 to $15.8 billion, with keytruda sales up 9% to $8 billion. The company announced strategic acquisitions, positive trial results, and FDA approvals, while narrowing its full-year sales outlook to $64.3-$65.3 billion and EPS to $8.87-$8.97. A multiyear cost-saving initiative and investments in manufacturing and R&D are also highlighted.